1Gómez Sáez J M. Diagnostic and prognostic markers in differentiated thyroid cancer[J]. Curr Genomics, 2011,12(8):597-608.
2Xing M, Alzahrani A S, Carson K A, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J]. JAMA, 2013,309(14):1493-501.
3Ahn D, Park J S, Sohn J H, et al. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma[J]. Auris Nasus Larynx, 2012,39(2):198-203.
4Fallahi P, Mazzi V, Vita R, et al. New therapies for dedifferentiated papillary thyroid cancer[J]. Int J Mol Sci, 2015,16(3):6153-82.
5Baquero P, Sánchez-Hernández I, Jiménez-Mora E, et al.(V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism[J]. Cancer Lett, 2013,335(1):232-41.
6Fukahori M, Yoshida A, Hayashi H, et al. The association between Ras gene mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort[J]. Thyroid, 2012,22(7):683-9.
7Gupta N, Dasyam A K, Carty S E, et al. Ras mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers[J]. J Clin Endocrinol Metab, 2013,98(5):914-22.
8Guerra A, Sapio M R, Marotta V, et al. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application[J]. Endocr J, 2011,58(1):31-8.
9Borrello M G, Ardini E, Locati L D, et al. RET inhibition: implications in cancer therapy[J]. Expert Opin Ther Targets, 2013,17(4):403-19.
10Salehian B, Samoa R. RET gene abnormalities and thyroid disease: Who should be screened and when[J]. J Clin Res Pediatr Endocrinol, 2013,5(1):70-8.
